Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells

Federico A. Steiner, Julie A. Hong, Maria R. Fischette, David G. Beer, Zong Sheng Guo, G. Aaron Chen, Todd S. Weiser, Edmund S. Kassis, Dao Nguyen, Sunmin Lee, Jane B. Trepel, David S. Schrump

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2′-deoxycytidine (BAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment indnced TFPI-2 in cancer eels deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer lines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediaied TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and UDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.

Original languageEnglish
Pages (from-to)2386-2397
Number of pages12
JournalOncogene
Volume24
Issue number14
DOIs
StatePublished - Mar 31 2005
Externally publishedYes

Fingerprint

decitabine
Depsipeptides
Neoplasms
Methylation
tissue-factor-pathway inhibitor 2
romidepsin

Keywords

  • 5-aza 2′-deoxycytidine
  • Depsipeptide FK228
  • Esophageal cancer
  • Lung cancer
  • TFPI-2

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Steiner, F. A., Hong, J. A., Fischette, M. R., Beer, D. G., Guo, Z. S., Chen, G. A., ... Schrump, D. S. (2005). Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene, 24(14), 2386-2397. https://doi.org/10.1038/sj.onc.1208376

Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. / Steiner, Federico A.; Hong, Julie A.; Fischette, Maria R.; Beer, David G.; Guo, Zong Sheng; Chen, G. Aaron; Weiser, Todd S.; Kassis, Edmund S.; Nguyen, Dao; Lee, Sunmin; Trepel, Jane B.; Schrump, David S.

In: Oncogene, Vol. 24, No. 14, 31.03.2005, p. 2386-2397.

Research output: Contribution to journalArticle

Steiner, FA, Hong, JA, Fischette, MR, Beer, DG, Guo, ZS, Chen, GA, Weiser, TS, Kassis, ES, Nguyen, D, Lee, S, Trepel, JB & Schrump, DS 2005, 'Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells', Oncogene, vol. 24, no. 14, pp. 2386-2397. https://doi.org/10.1038/sj.onc.1208376
Steiner, Federico A. ; Hong, Julie A. ; Fischette, Maria R. ; Beer, David G. ; Guo, Zong Sheng ; Chen, G. Aaron ; Weiser, Todd S. ; Kassis, Edmund S. ; Nguyen, Dao ; Lee, Sunmin ; Trepel, Jane B. ; Schrump, David S. / Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. In: Oncogene. 2005 ; Vol. 24, No. 14. pp. 2386-2397.
@article{7110744e110c4659890f87870cec2592,
title = "Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells",
abstract = "cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2′-deoxycytidine (BAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment indnced TFPI-2 in cancer eels deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer lines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediaied TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and UDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.",
keywords = "5-aza 2′-deoxycytidine, Depsipeptide FK228, Esophageal cancer, Lung cancer, TFPI-2",
author = "Steiner, {Federico A.} and Hong, {Julie A.} and Fischette, {Maria R.} and Beer, {David G.} and Guo, {Zong Sheng} and Chen, {G. Aaron} and Weiser, {Todd S.} and Kassis, {Edmund S.} and Dao Nguyen and Sunmin Lee and Trepel, {Jane B.} and Schrump, {David S.}",
year = "2005",
month = "3",
day = "31",
doi = "10.1038/sj.onc.1208376",
language = "English",
volume = "24",
pages = "2386--2397",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "14",

}

TY - JOUR

T1 - Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells

AU - Steiner, Federico A.

AU - Hong, Julie A.

AU - Fischette, Maria R.

AU - Beer, David G.

AU - Guo, Zong Sheng

AU - Chen, G. Aaron

AU - Weiser, Todd S.

AU - Kassis, Edmund S.

AU - Nguyen, Dao

AU - Lee, Sunmin

AU - Trepel, Jane B.

AU - Schrump, David S.

PY - 2005/3/31

Y1 - 2005/3/31

N2 - cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2′-deoxycytidine (BAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment indnced TFPI-2 in cancer eels deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer lines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediaied TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and UDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.

AB - cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2′-deoxycytidine (BAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment indnced TFPI-2 in cancer eels deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer lines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediaied TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and UDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.

KW - 5-aza 2′-deoxycytidine

KW - Depsipeptide FK228

KW - Esophageal cancer

KW - Lung cancer

KW - TFPI-2

UR - http://www.scopus.com/inward/record.url?scp=20144388727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144388727&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208376

DO - 10.1038/sj.onc.1208376

M3 - Article

C2 - 15735751

AN - SCOPUS:20144388727

VL - 24

SP - 2386

EP - 2397

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 14

ER -